General Anesthesia Drugs Market Synopsis:
General Anesthesia Drugs Market Size Was Valued at USD 6.84 Billion in 2023, and is Projected to Reach USD 10.70 Billion by 2032, Growing at a CAGR of 5.10 % From 2024-2032.
The General Anesthesia Drugs Market is a segment in the pharmaceutical industry that deals with drugs that cause a temporary loss of sensation while a patient undergoes surgery or diagnosis. These drugs are administered in hospitals, outpatient surgical facilities, and other health care institutions. They include intravenous and inhalation anesthetics in a market that is segmented by different medical and surgical requirements.
The general anesthesia drugs market is growing at a very good rate in the global market mainly due to the increasing number of surgical procedures across the world. Higher rates of incidences of chronic diseases including cardiovascular diseases, cancers, and musculoskeletal disorders have also increased the need for surgeries, hence the anesthesia drugs. Further, there is improved standards of health care infrastructure and growth of surgical operations to the use of complex anesthetic drugs. Financial players are directing their capital to the construction of healthcare facilities that allow better surgical outcomes, especially through the improvement that coming out of developing countries.
An aging populace is catalyzing the growth of the market out of its current dimension. The elder citizens are more likely to undergo surgeries due to their status as sickness-prone which increases the risk of using general anesthesia drugs. However, the market is also facing some challenges such as worries on anesthesia-related mishaps, complications, strict regulatory necessities for prescriptions, and high costs for developing new formulations of the drug. However, constant innovation is expected to solve these challenges since the market remains on a growth trend in the subsequent years.
General Anesthesia Drugs Market Trend Analysis:
Innovations in Anesthesia Delivery Systems
- The market of anesthesia drugs is moving towards a concept of advanced delivery systems. Mandatory use of specific technologies such as target-controlled infusion (TCI) and closed loop systems is resulting in enhanced accuracy and effectiveness of anesthesia administration. These systems afford continuous observation of a patient’s physiological state, making it possible to administer drugs according to requirements. In addition, the approach to the use of artificial intelligence (AI) in anesthesia management is expanding. It shows that artificial intelligence is also being used to predict patients’ response and dose levels to reduce complications and improve in surgeries. Such innovations are and will be responsible for altering the landscape currently pushing more and more people across the world to use general anesthesia drugs.
Expanding Markets in Emerging Economies
- There are broad opportunities for the general anesthesia drugs market among the EEAs. Communities like Asia-Pacific, Latin America and the Middle East are experiencing progressive advancement in health care and accessibility of medical care. Rising state investments to enhance the availability of health care and increased surgical procedures because of the growing incidences of non-communicable diseases remain key drivers of the growth of this market. Further, increasing investment in these areas and the availability of local manufacturers have worked wonders to make anesthesia drugs cheaper and easily available to patients. Other need categories include those in rural and underserved markets that demonstrate that there is a great area for market players to tap into.
General Anesthesia Drugs Market Segment Analysis:
General Anesthesia Drugs Market is Segmented on the basis of drug molecule, route of administration, end user, and Region.
By Drug Molecule, Propofol drug segment is expected to dominate the market during the forecast period
- The global general anesthesia drugs market is likely to remain in the custody of Propofol, an intravenous anesthetic drug during the forecast period. Propofol is recognized for its faster action and brief postoperative SECRET time and has emerged as the best anesthetic for both the induction and maintenance of different surgeries. It is broadly beneficial in a variety of circumstances with sedation in mechanically ventilated obstetrics surgery patients in the intensive care unit. Due to the familiar safety profile of Propofol and its ability to be used it in modern anesthesia delivery systems, the product demand is also high. Because of the ongoing advancement of this drug to further improve its formulation and at the same time reduce side effects, it is evident that the Position of Propofol in the Market will continue to rise in the future.
By Route of Administration, the Intravenous Anesthesia segment expected to held the largest share
- Of all the segments, the intravenous anesthesia segment is expected to show the maximum market share owing to its application in today’s surgical procedures. Most intravenous anesthetics provide a rapid onset of action and are associated with predictable kinetics therefore they can be used for both short and long-duration surgery. Key anesthetic drugs comprising this segment are Propofol, Etomidate, and Ketamine which have fundamentally leveraged this segment’s dominance. Furthermore, this segment’s expansion is further enhanced by formulation technologies that enhance drug stability and efficacy. The constant growth in minimally invasive operations indicated that most such surgeries demand accurate and short-duration anesthetics, fuelling intravenous anesthesia demand further.
General Anesthesia Drugs Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America held the largest market share of general anesthesia drugs throughout the forecast period owing to advancements in healthcare industry and an increasing number of surgical procedures. The United States has a competitive role in this region as a predominantly technologically developed nation with high healthcare expenditures and the first to adopt new-era anesthesia applications. Increasing incidences of chronic diseases including cardiovascular diseases, cancer and orthopedic disorders have caused an increase in surgical procedures. Due to this, there has been a growth in the need for safe, cheap, and efficient anesthesia drugs.
- These key players and investments in research and development have greatly boosted the dominance of the market. Promising key market players in North America are working constantly on improving the performance of drugs, making them safer and more effective – this is a key factor in the growth of the market*. There is increased adoption of superior anesthesia medicines due to proficient regulation and pertinent reimbursement policies. Also, the credible supply chain that the region has developed guarantees the timely delivery of the drugs in hospitals and surgical centers. Multilateral partnerships between universities, hospitals, and drug makers are promoting the advancement of new anesthesia medications in North America, which currently controls more than half of the global market.
Active Key Players in the General Anesthesia Drugs Market:
- AbbVie Inc. (United States)
- AstraZeneca plc (United Kingdom)
- Baxter International Inc. (United States)
- B. Braun Melsungen AG (Germany)
- Fresenius SE & Co. KGaA (Germany)
- Glenmark Pharmaceuticals Ltd. (India)
- Hikma Pharmaceuticals PLC (United Kingdom)
- Jiangsu Hengrui Medicine Co., Ltd. (China)
- Lupin Limited (India)
- Pacira BioSciences, Inc. (United States)
- Pfizer Inc. (United States)
- Piramal Enterprises Limited (India)
- Sandoz International GmbH (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Viatris Inc. (United States)
- Other Active Players
|
General Anaesthesia Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 6.84 Billion |
|
Forecast Period 2024-32 CAGR: |
5.10 % |
Market Size in 2032: |
USD 10.70 Billion |
|
Segments Covered: |
By Drug Molecule |
|
|
|
By Route of Administration |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: General Anesthesia Drugs Market by Drug Molecule
4.1 General Anesthesia Drugs Market Snapshot and Growth Engine
4.2 General Anesthesia Drugs Market Overview
4.3 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine: Geographic Segmentation Analysis
Chapter 5: General Anesthesia Drugs Market by Route of Administration
5.1 General Anesthesia Drugs Market Snapshot and Growth Engine
5.2 General Anesthesia Drugs Market Overview
5.3 Intravenous Anesthesia Inhalation Anesthesia
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Intravenous Anesthesia Inhalation Anesthesia: Geographic Segmentation Analysis
Chapter 6: General Anesthesia Drugs Market by End User
6.1 General Anesthesia Drugs Market Snapshot and Growth Engine
6.2 General Anesthesia Drugs Market Overview
6.3 Hospital Specialty Clinics Ambulatory Surgical Centers
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Specialty Clinics Ambulatory Surgical Centers: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 General Anesthesia Drugs Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBVIE INC. (UNITED STATES)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 ASTRAZENECA PLC (UNITED KINGDOM)
7.4 BAXTER INTERNATIONAL INC. (UNITED STATES)
7.5 B. BRAUN MELSUNGEN AG (GERMANY)
7.6 FRESENIUS SE & CO. KGAA (GERMANY)
7.7 GLENMARK PHARMACEUTICALS LTD. (INDIA)
7.8 HIKMA PHARMACEUTICALS PLC (UNITED KINGDOM)
7.9 JIANGSU HENGRUI MEDICINE CO. LTD. (CHINA)
7.10 LUPIN LIMITED (INDIA)
7.11 PACIRA BIOSCIENCES INC. (UNITED STATES)
7.12 PFIZER INC. (UNITED STATES)
7.13 PIRAMAL ENTERPRISES LIMITED (INDIA)
7.14 SANDOZ INTERNATIONAL GMBH (GERMANY)
7.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
7.16 VIATRIS INC. (UNITED STATES)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global General Anesthesia Drugs Market By Region
8.1 Overview
8.2. North America General Anesthesia Drugs Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Molecule
8.2.4.1 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
8.2.5 Historic and Forecasted Market Size By Route of Administration
8.2.5.1 Intravenous Anesthesia Inhalation Anesthesia
8.2.6 Historic and Forecasted Market Size By End User
8.2.6.1 Hospital Specialty Clinics Ambulatory Surgical Centers
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe General Anesthesia Drugs Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Molecule
8.3.4.1 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
8.3.5 Historic and Forecasted Market Size By Route of Administration
8.3.5.1 Intravenous Anesthesia Inhalation Anesthesia
8.3.6 Historic and Forecasted Market Size By End User
8.3.6.1 Hospital Specialty Clinics Ambulatory Surgical Centers
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Russia
8.3.7.2 Bulgaria
8.3.7.3 The Czech Republic
8.3.7.4 Hungary
8.3.7.5 Poland
8.3.7.6 Romania
8.3.7.7 Rest of Eastern Europe
8.4. Western Europe General Anesthesia Drugs Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Molecule
8.4.4.1 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
8.4.5 Historic and Forecasted Market Size By Route of Administration
8.4.5.1 Intravenous Anesthesia Inhalation Anesthesia
8.4.6 Historic and Forecasted Market Size By End User
8.4.6.1 Hospital Specialty Clinics Ambulatory Surgical Centers
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 The Netherlands
8.4.7.5 Italy
8.4.7.6 Spain
8.4.7.7 Rest of Western Europe
8.5. Asia Pacific General Anesthesia Drugs Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Molecule
8.5.4.1 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
8.5.5 Historic and Forecasted Market Size By Route of Administration
8.5.5.1 Intravenous Anesthesia Inhalation Anesthesia
8.5.6 Historic and Forecasted Market Size By End User
8.5.6.1 Hospital Specialty Clinics Ambulatory Surgical Centers
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa General Anesthesia Drugs Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Molecule
8.6.4.1 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
8.6.5 Historic and Forecasted Market Size By Route of Administration
8.6.5.1 Intravenous Anesthesia Inhalation Anesthesia
8.6.6 Historic and Forecasted Market Size By End User
8.6.6.1 Hospital Specialty Clinics Ambulatory Surgical Centers
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkiye
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America General Anesthesia Drugs Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Molecule
8.7.4.1 Desflurane Isoflurane Sevoflurane Propofol Etomidate Methohexital Thiopentone Midazolam Ketamine
8.7.5 Historic and Forecasted Market Size By Route of Administration
8.7.5.1 Intravenous Anesthesia Inhalation Anesthesia
8.7.6 Historic and Forecasted Market Size By End User
8.7.6.1 Hospital Specialty Clinics Ambulatory Surgical Centers
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
General Anaesthesia Drugs Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 6.84 Billion |
|
Forecast Period 2024-32 CAGR: |
5.10 % |
Market Size in 2032: |
USD 10.70 Billion |
|
Segments Covered: |
By Drug Molecule |
|
|
|
By Route of Administration |
|
||
|
By End User |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
